Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

[1]  Ryou-u Takahashi,et al.  Targeting DNA binding proteins for cancer therapy , 2020, Cancer science.

[2]  D. Lambrechts,et al.  Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing , 2019, Molecular Cancer Therapeutics.

[3]  C. Haslinger,et al.  Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules , 2018 .

[4]  C. Haslinger,et al.  Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic , 2018, Experimental and Molecular Therapeutics.

[5]  C. Haslinger,et al.  Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer , 2018, Experimental and Molecular Therapeutics.

[6]  M. Duffy,et al.  Mutant p53 as a target for cancer treatment. , 2017, European journal of cancer.

[7]  R. Sciot,et al.  In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models , 2017, Molecular Cancer Therapeutics.

[8]  J. Schellens,et al.  A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. , 2017, European journal of cancer.

[9]  Philipp Holzer,et al.  Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. , 2016, Bioorganic & medicinal chemistry letters.

[10]  Joon Sang Lee,et al.  TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma , 2016, Nature Communications.

[11]  W. Vainchenker,et al.  P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis , 2016, Oncotarget.

[12]  David M. Thomas,et al.  Clinical Overview of MDM2/X-Targeted Therapies , 2016, Front. Oncol..

[13]  C. Creighton,et al.  SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma , 2015, Clinical Cancer Research.

[14]  P. Vyas,et al.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia , 2015, Clinical Cancer Research.

[15]  R. Sciot,et al.  Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models , 2014, Translational oncology.

[16]  P. Schöffski,et al.  Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease , 2014, Oncology Research and Treatment.

[17]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[18]  Kelli J. Glenn,et al.  Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. , 2014, Experimental hematology.

[19]  M. Freeman,et al.  Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ , 2013, PloS one.

[20]  J. Blay,et al.  Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS). , 2013 .

[21]  Binh Vu,et al.  MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. , 2013, Cancer research.

[22]  Jean-Yves Blay,et al.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.

[23]  V. Baladandayuthapani,et al.  Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA , 2012, Molecular Cancer Therapeutics.

[24]  J. Blay,et al.  Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Blay,et al.  A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. , 2012 .

[26]  R. Breitling,et al.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells , 2011, Cell Death and Disease.

[27]  C. Maki,et al.  Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 , 2011, Oncogene.

[28]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[29]  J. Goldblum,et al.  Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. , 1997, The American journal of surgical pathology.

[30]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[31]  D. A. Gomes,et al.  Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography. , 2013, Journal of cancer science & therapy.

[32]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .